Dark

NTLA
Intellia Therapeutics, Inc
stock NASDAQ

At Close

May 29, 2025 3:59:57 PM EDT

7.44USD-22.981%(-2.22)24,187,158

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 29, 2025 9:28:30 AM EDT

7.37USD-23.706%(-2.29)1,051,666

After-hours

May 29, 2025 4:58:30 PM EDT

7.40USD-0.538%(-0.04)25,063

OverviewOptionsHistoricalExchangesShortsNews

Jan 31, 2022

10:34AM EST $100 Invested In This Stock 5 Years Ago, Would Be Worth This Much Benzinga

10:29AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 Benzinga

09:18AM EST Analyst Ratings For Intellia Therapeutics Benzinga

07:15AM EST Cowen & Co. Initiates Coverage On Intellia Therapeutics with Outperform Rating Benzinga

Jan 13, 2022

02:08PM EST If You Invested $1000 In This Stock 5 Years Ago, Here's How Much You Would Have Today Benzinga

Jan 7, 2022

01:08PM EST What 4 Analyst Ratings Have To Say About Intellia Therapeutics Benzinga

01:07PM EST Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022 Benzinga

01:03PM EST JMP Securities Maintains Market Outperform on Intellia Therapeutics, Lowers Price Target to $165 Benzinga

01:02PM EST Piper Sandler Initiates Coverage On Intellia Therapeutics with Overweight Rating, Announces Price Target of $171 Benzinga

Jan 6, 2022

07:37AM EST Intellia Therapeutics Highlights Strategic Priorities And Anticipated Development Milestones For 2022 Benzinga

07:30AM EST Intellia Therapeutics Highlights Strategic Priorities and GlobeNewswire Inc

Jan 5, 2022

04:01PM EST Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced that the company is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET. GlobeNewswire Inc

07:32AM EST Intellia Therapeutics And Kyverna Therapeutics Announce Collaboration To Develop Next-Generation Allogeneic T-Cell Therapy For Autoimmune Diseases Benzinga

07:30AM EST Intellia grants Kyverna exclusive rights to its differentiated allogeneic cell engineering platform for the development of KYV-201, a next-generation CD19 CAR T-cell therapy to treat autoimmune diseases GlobeNewswire Inc

Dec 20, 2021

07:40AM EST Intellia Therapeutics Appoints Derek Hicks As Chief Business Officer RTTNews

07:30AM EST Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of Derek Hicks to a newly created position as Executive Vice President, Chief Business Officer. GlobeNewswire Inc

Dec 14, 2021

02:51PM EST CRISPR Therapeutics Shares Move Higher; Elon Musk, Responding To Gene Editing Article, Says 'This is the revolution in medicine' Benzinga

Dec 13, 2021

07:40AM EST Intellia Therapeutics Doses First Patient In Phase 1/2 Clinical Trial Of NTLA-2002 For Hereditary Angioedema RTTNews

07:35AM EST Intellia Therapeutics Announces First Patient Dosed In Phase 1/2 Clinical Trial Of NTLA-2002 For The Treatment Of Hereditary Angioedema Benzinga

07:30AM EST Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 GlobeNewswire Inc

Nov 22, 2021

07:37AM EST Intellia Therapeutics Expands Phase 1 Study Of NTLA-2001 For Adults With Transthyretin Amyloidosis With Cardiomyopathy RTTNews

07:30AM EST Intellia Therapeutics Announces Expansion of Ongoing Phase 1 GlobeNewswire Inc

Nov 5, 2021

09:46AM EDT Oppenheimer Maintains Perform on Intellia Therapeutics, Lowers Price Target to $145 Benzinga

09:40AM EDT Intellia Therapeutics To Highlight Ex Vivo Genome Editing, CRISPR/Cas9 Manufacturing Advances At 2021 American Society Of Hematology Annual Meeting Benzinga

09:38AM EDT HC Wainwright & Co. Maintains Buy on Intellia Therapeutics, Raises Price Target to $182 Benzinga

07:30AM EDT Intellia Therapeutics to Highlight Ex Vivo Genome Editing and GlobeNewswire Inc

Nov 4, 2021

08:19AM EDT The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO Benzinga

07:48AM EDT Intellia Therapeutics Q3 EPS $(0.97) Misses $(0.84) Estimate, Sales $7.20M Miss $8.66M Estimate Benzinga

07:30AM EDT Intellia Therapeutics Announces Third Quarter 2021 Financial GlobeNewswire Inc

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Nov 1, 2021

09:04AM EDT Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Oct. 29, 2021: NTLA, PACB, ACHR, MKFG, BLDE, FB, CDNA, DOC, EXAS, VERV, BEAM Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 28, 2021

07:30AM EDT Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its third quarter 2021 financial results and operational highlights in a conference call on November 4, 2021 at 8 a.m. ET. GlobeNewswire Inc

Oct 21, 2021

12:11PM EDT Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation For NTLA-2001, An Investigational CRISPR Therapy For The Treatment Of Transthyretin Amyloidosis Benzinga

07:30AM EDT Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation GlobeNewswire Inc

Oct 20, 2021

10:42AM EDT Intellia Therapeutics Shares Quiet As Traders Circulate Oct. 19-Dated AccessData.FDA.gov Listing For Orphan Drug Designation Of Co.'s Transtheyretin Amyloidosis Treatment Benzinga

07:40AM EDT Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements In Its Broad Genome Editing Capabilities At The 2021 European Society Of Gene & Cell Therapy Annual Congress Benzinga

07:30AM EDT Intellia Therapeutics Presents Preclinical Data Demonstrating GlobeNewswire Inc

Oct 13, 2021

01:38PM EDT The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal Benzinga

01:38PM EDT Intellia Therapeutics and SparingVision Announce Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology; Intellia To Receive 10% Equity Ownership Stake In SparingVision And Up To $200M/Product In Milestones Benzinga

07:01AM EDT Intellia Therapeutics and SparingVision Announce Strategic GlobeNewswire Inc

Oct 12, 2021

07:30AM EDT Intellia Therapeutics to Present New Preclinical Data Highlighting GlobeNewswire Inc

Oct 8, 2021

10:26AM EDT Intellia Therapeutics, Inc. (NTLA) shares are trading down more than 8 percent on Friday morning trade, continuing a decline in search of new support. The shares have been on a downtrend since the start of September. There have been no stock-specific news today to drive down the stock. RTTNews

Oct 6, 2021

08:29AM EDT Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients Benzinga

07:33AM EDT Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema Benzinga

07:30AM EDT Intellia Therapeutics Receives Authorization to Initiate Phase GlobeNewswire Inc

Oct 5, 2021

10:14AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2021 Benzinga

07:19AM EDT Guggenheim Initiates Coverage On Intellia Therapeutics with Buy Rating, Announces Price Target of $170 Benzinga

Sep 27, 2021

07:40AM EDT Intellia Therapeutics To Present At Chardan's 5th Annual Genetic Medicines Conference Oct. 4 Benzinga

07:30AM EDT Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at Chardans 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 10:30 a.m. ET. GlobeNewswire Inc

Sep 24, 2021

01:54PM EDT Where Intellia Therapeutics Stands With Analysts Benzinga

10:43AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021 Benzinga

05:21AM EDT Stifel Initiates Coverage On Intellia Therapeutics with Buy Rating, Announces Price Target of $173 Benzinga

Sep 16, 2021

08:40AM EDT Intellia Therapeutics, Inc. (NTLA) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application for NTLA-5001, the company's first wholly-owned ex vivo CRISPR genome editing candidate for the treatment of cancer. RTTNews

08:03AM EDT Intellia Therapeutics: FDA Accepts NTLA-5001 IND For Acute Myeloid Leukemia RTTNews

07:32AM EDT Intellia Therapeutics Announces FDA Acceptance Of Investigational New Drug Application For NTLA-5001, Its CRISPR/Cas9-Engineered TCR-T Cell Candidate For Acute Myeloid Leukemia Benzinga

07:30AM EDT -- NTLA-5001 is Intellias first ex vivo candidate using its proprietary cell engineering process for the treatment of cancer to enter clinical study -- NTLA-5001 targets Wilms Tumor 1 (WT1), an overexpressed intracellular antigen on many hematologic malignancies and solid tumors -- Initiation of patient screening in Phase 1/2a study of NTLA-5001 expected by year-end GlobeNewswire Inc

Aug 31, 2021

07:30AM EDT Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the following virtual healthcare investor conferences in September: GlobeNewswire Inc

Aug 6, 2021

12:24PM EDT Where Intellia Therapeutics Stands With Analysts Benzinga

12:15PM EDT Raymond James Maintains Outperform on Intellia Therapeutics, Raises Price Target to $181 Benzinga

09:37AM EDT JMP Securities Maintains Market Outperform on Intellia Therapeutics, Raises Price Target to $175 Benzinga

09:08AM EDT Oppenheimer Maintains Perform on Intellia Therapeutics, Raises Price Target to $160 Benzinga

08:48AM EDT Goldman Sachs Maintains Buy on Intellia Therapeutics, Raises Price Target to $252 Benzinga

07:56AM EDT 10 Biggest Price Target Changes For Friday Benzinga

05:36AM EDT Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $177 Benzinga

Aug 5, 2021

08:10AM EDT Intellia Therapeutics Q2 EPS $(1.01) Misses $(0.63) Estimate, Sales $6.55M Miss $11.89M Estimate Benzinga

07:30AM EDT Intellia Therapeutics Announces Second Quarter 2021 Financial GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 4, 2021

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 29, 2021

07:30AM EDT Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its second quarter 2021 financial results and operational highlights in a conference call on August 5, 2021 at 8 a.m. E.T. GlobeNewswire Inc

Jul 21, 2021

11:49AM EDT Alzheimer's Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What's Next? Benzinga

Jul 12, 2021

03:12PM EDT WHO Issues Framework For Governance For Gene Editing Technologies Benzinga

Jul 2, 2021

04:01PM EDT Intellia Therapeutics Announces Closing of $690 Million Public GlobeNewswire Inc

Jul 1, 2021

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

05:48AM EDT Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders Benzinga

Jun 30, 2021

04:51PM EDT 'Halftime Report' Traders Share Their Thoughts On Crispr Therapeutics And Bed Bath & Beyond Benzinga

03:31PM EDT In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC Benzinga

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

07:11AM EDT Intellia Therapeutics Stock Moves Higher After Capital Raise Of $600M Issued At $145/Share Benzinga

Jun 29, 2021

09:08PM EDT Intellia Therapeutics Announces Pricing of Public Offering of GlobeNewswire Inc

01:00PM EDT Analyst Ratings For Intellia Therapeutics Benzinga

12:30PM EDT Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated Benzinga

11:41AM EDT UPDATE: Roth Capital On Intellia Therapeutics Buy Rating: Firm Highlights First-In-Human In Vivo Data As Providing 'Clinical Proof-Of-Concept And Validation To The Platform'. Benzinga

11:41AM EDT Roth Capital Maintains Buy Rating On Intellia Therapeutics, Price Target $110. Benzinga

08:18AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

08:17AM EDT The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout Benzinga

07:54AM EDT Oppenheimer Maintains Perform on Intellia Therapeutics, Raises Price Target to $125 Benzinga

07:28AM EDT Raymond James Maintains Outperform on Intellia Therapeutics, Raises Price Target to $168 Benzinga

06:58AM EDT Intellia Seeks To Raise $400M Via Equity Benzinga

Jun 28, 2021

05:05PM EDT Intellia Therapeutics Analyst Doubles Price Target: What You Need To Know Benzinga

04:01PM EDT Intellia Therapeutics Announces Proposed Public Offering of $400M Shares of Common Stock Benzinga

04:01PM EDT Intellia Therapeutics Announces Proposed Public Offering of Common GlobeNewswire Inc

02:40PM EDT Mid-Afternoon Market Update: Nasdaq Gains 100 Points; New Senior Investment Shares Spike Higher Benzinga

12:22PM EDT Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump Benzinga

11:23AM EDT CORRECTION: Alnylam Ticker Is 'ALNY' Benzinga

11:19AM EDT Chardan Research Maintains Buy Rating On Alnylam Pharmaceuticals, Price Target $190. Benzinga

11:13AM EDT UPDATE: Chardan Research On Intellia Therapeutics: Firm Believes If Durability Holds Up With No Longer-Term Safety Signals, NTLA-2001 'Has Potential To Be A Functional Cure For Amyloidosis'. Benzinga

11:13AM EDT Chardan Research Maintains Buy Rating On Intellia Therapeutics, Price Target $130. Benzinga

10:08AM EDT Shares of Intellia Therapeutics Inc. (NTLA) are surging nearly 50% on Monday morning driven by positive results from an ongoing early-stage study of its Crispr/CA9-based treatment for transthyretin amyloidosis, a protein-based disorder that often leads to heart failure. RTTNews

10:08AM EDT Mid-Morning Market Update: Markets Mixed; Perion Network Boosts FY21 Outlook Benzinga

09:19AM EDT Benzinga Pro's Top 5 Stocks To Watch For Monday, Jun. 28, 2021: CCL, NTLA, DDL, PRVB, WBA Benzinga

08:49AM EDT 10 Biggest Price Target Changes For Monday Benzinga

08:19AM EDT Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $87 Benzinga

07:57AM EDT Barclays Maintains Overweight on Intellia Therapeutics, Raises Price Target to $134 Benzinga

07:40AM EDT Goldman Sachs Maintains Buy on Intellia Therapeutics, Raises Price Target to $163 Benzinga

07:36AM EDT Truist Securities Maintains Buy on Intellia Therapeutics, Raises Price Target to $160 Benzinga

07:34AM EDT Roth Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $110 Benzinga

06:19AM EDT HC Wainwright & Co. Maintains Buy on Intellia Therapeutics, Raises Price Target to $171 Benzinga

06:09AM EDT Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate Benzinga

06:09AM EDT A Peek Into The Markets: US Stock Futures Mixed; Crude Oil Edges Lower Benzinga

05:44AM EDT Intellia Shares Up 29% Premarket After Company and Regeneron Announced on Saturday Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001 for Treatment of Transthyretin Amyloidosis Benzinga

04:42AM EDT Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $130 Benzinga

Jun 26, 2021

11:41AM EDT Intellia Therapeutics Inc. (NTLA) and Regeneron Pharmaceuticals Inc. (REGN) announced positive interim data from an ongoing phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001. The clinical data showed deep reduction in disease-causing protein after single infusion of NTLA-2001, an investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis. RTTNews

11:20AM EDT Intellia, Regeneron Announce Data Showing Deep Reduction In Disease-Causing Protein After Single Infusion Of NTLA-2001 RTTNews

11:16AM EDT in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis PR Newswire

11:15AM EDT Intellia and Regeneron Announce Landmark Clinical Data Showing GlobeNewswire Inc

Jun 24, 2021

07:32AM EDT Intellia Therapeutics Names James Basta EVP, General Counsel And Corporate Secretary RTTNews

07:30AM EDT Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary. GlobeNewswire Inc

Jun 23, 2021

11:48AM EDT Expert Ratings For Intellia Therapeutics Benzinga

08:03AM EDT JMP Securities Maintains Market Outperform on Intellia Therapeutics, Raises Price Target to $88 Benzinga

07:47AM EDT Baird Maintains Neutral on Intellia Therapeutics, Raises Price Target to $85 Benzinga

Jun 22, 2021

07:05AM EDT Blackstone Life Sciences, Cellex Cell Professionals, And Intellia Therapeutics Launch New CAR T-Cell Company RTTNews

Jun 17, 2021

04:22PM EDT Intellia Therapeutics On Jun. 14 Entered Amendment To Collaborative Research Agreement With Novartis; Amendment Amends Novartis' Rights With Respect To CAR-T Therapeutic Targets Under Agreement Benzinga

Jun 11, 2021

11:32AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021 Benzinga

06:30AM EDT HC Wainwright & Co. Initiates Coverage On Intellia Therapeutics with Buy Rating, Announces Price Target of $111 Benzinga

Jun 4, 2021

07:32AM EDT Intellia Therapeutics Highlights Will Present Interim Clinical Data From Ongoing Phase 1 Study Of NTLA-2001 For Treatment Of Transthyretin Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting Jun. 26 Benzinga

07:30AM EDT -- Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidate -- Late-breaking abstract selected for oral presentation on June 26 GlobeNewswire Inc

May 7, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 7, 2021 Benzinga

06:33AM EDT Roth Capital Upgrades Intellia Therapeutics to Buy, Raises Price Target to $80 Benzinga

May 6, 2021

08:44AM EDT Intellia Therapeutics Q1 EPS $(0.69) Misses $(0.67) Estimate, Sales $6.45M Miss $8.57M Estimate Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

07:30AM EDT -- Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloidosis (ATTR), in mid-2021 GlobeNewswire Inc

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

May 4, 2021

10:09AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2021 Benzinga

06:35AM EDT RBC Capital Initiates Coverage On Intellia Therapeutics with Outperform Rating, Announces Price Target of $110 Benzinga

Apr 29, 2021

07:30AM EDT Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its first quarter 2021 financial results and operational highlights in a conference call on May 6 at 8 a.m. E.T. GlobeNewswire Inc

Apr 12, 2021

07:36AM EDT Intellia Therapeutics Appoints Georgia Keresty To Board RTTNews

07:30AM EDT Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology bothin vivoandex vivo, today announced the appointment of Georgia Keresty, Ph.D., M.P.H.,tothe companysBoard of Directors. GlobeNewswire Inc

Apr 8, 2021

08:14AM EDT The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data Benzinga

Mar 30, 2021

07:31AM EDT Intellia Therapeutics' Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis Benzinga

07:30AM EDT Intellia Therapeutics Investigational CRISPR GlobeNewswire Inc

Mar 25, 2021

07:31AM EDT Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors Benzinga

07:30AM EDT Intellia Therapeutics Presents New Data on Expanded Cell GlobeNewswire Inc

Mar 10, 2021

07:35AM EST Intellia Therapeutics Highlights Presentation Of Preclinical Proof Of Concept For CRISPR-Based In Vivo Editing Of Bone Marrow At Keystone eSymposium Benzinga

07:30AM EST - Demonstrates the promise of Intellias proprietary non-viral delivery system for in vivo genome editing of tissues outside the liver, with applications to inherited blood disorders such as sickle cell disease GlobeNewswire Inc

Mar 4, 2021

10:10AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 4, 2021 Benzinga

08:08AM EST JMP Securities Initiates Coverage On Intellia Therapeutics with Outperform Rating, Announces Price Target of $80 Benzinga

Feb 25, 2021

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

07:59AM EST Intellia Therapeutics Q4 EPS $(0.69) Misses $(0.60) Estimate, Sales $6.59M Miss $14.09M Estimate Benzinga

07:30AM EST Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 GlobeNewswire Inc

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 18, 2021

07:30AM EST Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its fourth quarter and full-year 2020 financial results and operational highlights in a conference call on February 25, 2021 at 8 a.m. ET. GlobeNewswire Inc

Feb 10, 2021

10:22AM EST Intellia Therapeutics shares were trading higher after Chardan Capital maintained its Buy rating on the stock and raised its price target from $57.50 to $85 per share. Benzinga

10:06AM EST Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $85 Benzinga

Jan 8, 2021

11:04AM EST Raymond James Maintains Outperform on Intellia Therapeutics, Raises Price Target to $106 Benzinga

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

Jan 7, 2021

07:35AM EST Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021 Benzinga

07:30AM EST Intellia Therapeutics Highlights Strategic Priorities and GlobeNewswire Inc

Dec 29, 2020

08:09AM EST The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Benzinga

Dec 22, 2020

10:02AM EST Benzinga's Top Upgrades, Downgrades For December 22, 2020 Benzinga

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

06:27AM EST Baird Downgrades Intellia Therapeutics to Neutral Benzinga

Dec 21, 2020

10:08AM EST SVB Leerink Reiterates Outperform on Intellia Therapeutics, Raises Price Target to $61 Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 12, 2020

09:00AM EST Demonstrates modularity of Intellias in vivo liver insertion technology to durably restore protein, compared to traditional gene therapy GlobeNewswire Inc

Dec 11, 2020

08:11AM EST The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Dec 5, 2020

10:00AM EST Intellia Therapeutics Presents New Preclinical Data Supporting Its GlobeNewswire Inc

Dec 4, 2020

04:01PM EST Intellia Therapeutics Announces Closing of $201 Million Public GlobeNewswire Inc

08:04AM EST The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs Benzinga

Dec 1, 2020

09:30PM EST Intellia Therapeutics Announces Pricing of Public Offering of GlobeNewswire Inc

08:08AM EST The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga

Nov 30, 2020

04:01PM EST Intellia Therapeutics Announces Proposed Public Offering of Common GlobeNewswire Inc

04:01PM EST Intellia Therapeutics Reports $150M Common Stock Offering Benzinga

Nov 19, 2020

08:17AM EST The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway Benzinga

Nov 18, 2020

07:30AM EST The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted Benzinga

Nov 17, 2020

08:32AM EST The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration Benzinga

Nov 16, 2020

10:02AM EST 68 Stocks Trading Near 52-Week Highs Just After Open On Monday, Nov. 16, 2020: Benzinga

Nov 11, 2020

07:34AM EST Intellia Therapeutics Receives Grant To Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments; Amount Not Disclosed Benzinga

07:30AM EST Funding from the Bill & Melinda Gates Foundation to develop safe, scalable and accessible non-viral treatments for sickle cell patients GlobeNewswire Inc

Nov 10, 2020

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

Nov 9, 2020

07:42AM EST Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis Benzinga

07:30AM EST NTLA-2001: First single-course therapy that potentially halts and reverses ATTR progression GlobeNewswire Inc

Nov 6, 2020

07:47AM EST The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga

Nov 5, 2020

09:52AM EST 68 Stocks Trading Near 52-Week Highs Just After Open On Thursday, Nov. 5, 2020: Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

07:47AM EST Intellia Therapeutics Q3 EPS $(0.47) Beats $(0.59) Estimate, Sales $22.22M Beat $15.58M Estimate Benzinga

07:30AM EST Intellia Therapeutics Announces Third Quarter 2020 Financial Results GlobeNewswire Inc

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

08:59AM EST Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 29, 2020

07:30AM EDT Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its third quarter 2020 financial results and operational highlights in a conference call on November 5, 2020 at 8 a.m. ET. GlobeNewswire Inc

Oct 27, 2020

10:35AM EDT Benzinga's Top Upgrades, Downgrades For October 27, 2020 Benzinga

07:52AM EDT Truist Securities Initiates Coverage On Intellia Therapeutics with Buy Rating, Announces Price Target of $40 Benzinga

Oct 19, 2020

07:32AM EDT Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis Benzinga

07:30AM EDT NTLA-2001: First single-course therapy that potentially halts and reverses ATTR GlobeNewswire Inc

Oct 14, 2020

10:01AM EDT Benzinga's Top Upgrades, Downgrades For October 14, 2020 Benzinga

06:59AM EDT Wells Fargo Initiates Coverage On Intellia Therapeutics with Overweight Rating Benzinga

Oct 8, 2020

08:16AM EDT Benzinga Pro's Top 5 Stocks To Watch For Thursday, Oct. 8, 2020: TSLA, JNJ, ROKU, IH, EDIT Benzinga

Oct 7, 2020

04:20PM EDT Today, Jennifer Doudna, Ph.D., one of Intellia Therapeutics, Inc.s scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry for the development of the CRISPR/Cas9 genome editing technology. Dr. Doudna shared the award with her research collaborator, Dr. Emmanuelle Charpentier. This is the first time two women scientists have jointly won a Nobel Prize in Chemistry. GlobeNewswire Inc

Oct 5, 2020

07:30AM EDT Intellia Therapeutics Names John F. Crowley to Board of Directors GlobeNewswire Inc

Sep 29, 2020

08:21AM EDT Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing And Durability Of Effect Following CRISPR/Cas9-Based Treatment Benzinga

08:20AM EDT In Vivo gene knockout and insertion data to be presented at OTS Annual Meetinghighlightmodularity ofIntellias platformandpotentialforvariety of single-course therapies,with companys first systemictreatment (NTLA-2001)expected to enter the clinic by year-end GlobeNewswire Inc

Sep 28, 2020

08:00AM EDT Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at Chardans Virtual 4th Annual Genetic Medicines Conference on Monday, October 5, 2020 at 9 a.m. ET. GlobeNewswire Inc

Sep 18, 2020

09:31AM EDT Benzinga's Top Upgrades, Downgrades For September 18, 2020 Benzinga

08:06AM EDT Goldman Sachs Initiates Coverage On Intellia Therapeutics with Buy Rating, Announces Price Target of $33 Benzinga

Sep 2, 2020

08:00AM EDT Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at Bairds 2020 Virtual Global Healthcare Conference on Wednesday, September 9, 2020 at 10:50 a.m. ET. GlobeNewswire Inc

Aug 6, 2020

08:20AM EDT Intellia Therapeutics Q2 EPS $(0.61) Beats $(0.69) Estimate, Sales $16.26M Beat $8.54M Estimate Benzinga

07:30AM EDT Intellia Therapeutics Announces Second Quarter 2020 Financial Results GlobeNewswire Inc

Aug 3, 2020

08:00AM EDT Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 3:30 p.m. ET. GlobeNewswire Inc

Jul 30, 2020

07:30AM EDT Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its second quarter 2020 financial results and operational highlights in a conference call on August 6, 2020 at 8 a.m. ET. GlobeNewswire Inc

Jul 20, 2020

08:04AM EDT GEMoaB And Intellia Therapeutics Enter Into Research Collaboration And Licensing Agreement On Next-Generation Cellular Immunotherapy Based On Proprietary RevCAR And CRISPR/Cas9 Genome Editing Platforms Benzinga